ADC360: From antibody to conjugate – building an integrated path to the clinic

What does it actually take to turn a promising antibody-drug conjugate (ADC) concept into a robust, scalable and clinic-ready product?

This webinar brings together perspectives from across the ADC development journey to explore how integrated biologics manufacturing, ADC technologies and advanced analytics can help de-risk development and accelerate the path toward clinical manufacturing.

From therapeutic concept and molecule design, through antibody development and manufacturing, linker and payload selection, conjugation, analytical characterisation and process scale-up, to GMP manufacturing and clinical supply, the session will provide a 360-degree view of the complex journey behind a successful ADC.

Industry experts will discuss the critical interfaces between each stage of development and explore how early integration, coordinated development strategies and effective collaboration between specialised partners can reduce risk, improve scalability and prevent challenges from emerging later in the development process.

Through the perspectives of an ADC innovator, biologics and CMC experts, and ADC development specialists, ADC360 will demonstrate that successful ADC development is not simply about excellence at individual stages. It is about connecting the right capabilities, expertise and data into one integrated development path.

Join us to explore how a promising molecule can move from concept to a scalable, controlled and clinic-ready product, and why successful ADC development starts long before conjugation.